Disseminated tumor cell (DTC)

Disseminated tumor cells (DTCs) are individual malignant cells that have migrated from a primary tumor to distant tissues, most commonly the bone marrow, often before a patient presents with symptoms of metastatic disease [3, 11]. These cells represent the biological foundation of minimal residual disease and are the primary precursors of clinical recurrence and late-stage metastasis [1, 10]. A critical challenge in oncology is that many DTCs enter a state of dormancy or quiescence, allowing them to survive for long periods while evading conventional chemotherapies that target rapidly dividing cells [3, 18]. Pharmacological targeting of DTCs involves the use of antibodies against specific markers like HER2 or EpCAM, as well as agents that alter the metastatic niche—such as bisphosphonates or RANKL inhibitors—to prevent colonization and survival [1, 13, 18]. Understanding the molecular mechanisms that maintain DTC dormancy or trigger their reactivation is vital for developing therapies that can achieve true cancer cure by preventing relapse [7, 8].

Other names

MicrometastasisDormant cancer cellOccult tumor cellBone marrow disseminated tumor cell

Drugs targeting disseminated tumor cells (DTCs) function by either directly eliminating the cells via monoclonal antibodies that recognize surface antigens (e.g., HER2, EpCAM) or by disrupting the protective microenvironmental niches that support cell survival and dormancy [1, 13, 18]. Some strategies focus on inhibiting the transition of dormant DTCs into proliferative macrometastases or sensitizing them to chemotherapy by blocking niche-mediated survival signaling [10, 18].